Physician profile
Ajay N Mathur
NPI 1053357947
$4,599.25
in general payments reported to CMS, 2019-2025
21 companies · $771 in 2025
The $771 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $662 · 2021: $696 · 2022: $502 · 2023: $620 · 2024: $582 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $847.02 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $757.83 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Gilead Sciences, INC. | $706.43 | 2019-2025 | |
| Insmed, INC. | $490.04 | 2019-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $433.84 | 2020-2025 | Nuzyra |
| Abbvie INC. | $330.23 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $185.51 | 2023-2025 | Vowst |
| Astellas Pharma US INC | $160.22 | 2019-2024 | Cresemba |
| Melinta Therapeutics, LLC | $154.62 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Allergan, INC. | $123.90 | 2019-2020 | |
| Theratechnologies INC. | $87.57 | 2023-2025 | Egrifta, Trogarzo |
| Shionogi INC | $76.43 | 2024-2025 | Fetroja |
| Ferring Pharmaceuticals INC. | $57.31 | 2023 | Rebyota |
| Janssen Biotech, INC. | $45.31 | 2022-2023 | Symtuza |
| Pfizer INC. | $31.40 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $28.53 | 2021-2022 | |
| Daiichi Sankyo INC. | $20.89 | 2019 | |
| La Jolla Pharmaceutical Company | $18.57 | 2024 | Xacduro |
| Alexion Pharmaceuticals, INC. | $15.88 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $14.04 | 2019 | |
| Vyera Pharmaceuticals, LLC | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.